Beta Bionics Funding & Investors
Irvine, CA
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
betabionics.comTotal Amount Raised: $353,452,928
Beta Bionics Funding Rounds
Series E
$60,000,000
Series E Investors
Wellington ManagementOmega Fund ManagementSoleus CapitalMarshall WacePerceptive AdvisorsSands Capital ManagementRTW InvestmentsEventideSeries E
$60,000,000
Series E Investors
Wellington ManagementOmega Fund ManagementSoleus CapitalMarshall WacePerceptive AdvisorsSands Capital ManagementRTW InvestmentsEventideSeries D
$100,000,000
Series D Investors
Omega Fund ManagementSands Capital ManagementArrowMark Colorado HoldingsEventideRTW InvestmentsSoleus CapitalFarallon Capital ManagementPerceptive AdvisorsPura Vida InvestmentsMarshall WaceLifeSci Venture PartnersSeries D
$100,000,000
Series D Investors
Omega Fund ManagementSands Capital ManagementArrowMark Colorado HoldingsEventideRTW InvestmentsSoleus CapitalFarallon Capital ManagementPerceptive AdvisorsPura Vida InvestmentsMarshall WaceLifeSci Venture PartnersSeries C
$57,000,000
Series C Investors
EventideFarallon Capital ManagementPerceptive AdvisorsRTW InvestmentsSoleus CapitalPura Vida InvestmentsNovo NordiskLifeSci Venture PartnersArrowMark Colorado HoldingsSeries C
$57,000,000
Series C Investors
EventideFarallon Capital ManagementPerceptive AdvisorsRTW InvestmentsSoleus CapitalPura Vida InvestmentsNovo NordiskLifeSci Venture PartnersArrowMark Colorado HoldingsSeries B
$63,000,000
Series B Investors
Perceptive AdvisorsSoleus CapitalFarallon Capital ManagementArrowMark Colorado HoldingsRTW InvestmentsEventideSeries B
$63,000,000
Series B Investors
Perceptive AdvisorsSoleus CapitalFarallon Capital ManagementArrowMark Colorado HoldingsRTW InvestmentsEventideSeries B
$63,000,000
Series B Investors
EventideRTW InvestmentsDexcomZealand Pharma A/SLifeSci Venture PartnersArrowMark Colorado HoldingsSeries B
$63,000,000
Series B Investors
EventideRTW InvestmentsDexcomZealand Pharma A/SLifeSci Venture PartnersArrowMark Colorado HoldingsGrant
$2,000,000
Grant Investors
national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddkGrant
$2,000,000
Grant Investors
national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddkSeries Unknown
$2,452,916
Series Unknown
$2,452,916
Equity Crowdfunding
$1,000,000
Equity Crowdfunding
$1,000,000
Series A
$5,000,000
Series A Investors
Eli Lilly and CompanyNovo NordiskSeries A
$5,000,000
Series A Investors
Eli Lilly and CompanyNovo Nordisk